Trial Profile
10-year clinical and cost effectiveness results from the Risk Sharing Scheme for Glatiramer acetate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2018
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 14 Nov 2018 Results assessing the assess the clinical- and cost-effectiveness of GA using the final, 10-year data from the RSS, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 30 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis